Angioimmunoblastic T-Cell Lymphoma: Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission.
The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Some drugs that are used for other lymphomas may at times be considered for use in patients with angioimmunoblastic t-cell lymphoma (AITL) that has relapsed or is refractory to other treatments, including:
- Alemtuzumab (Campath)
- Bendamustine (Treanda)
- Bortezomib (Velcade)
- Fludarabine (Fludara)
- Gemcitabine (Gemzar)
- Pralatrexate (Folotyn)
- Rituximab (Rituxan)
- Romidepsin (Istodax)
- Belinostat (Beleodaq)
To learn more about angioimmunoblastic T-cell lymphoma, download the AITL Factsheet.
Patients may also want to consider a clinical trial for relapsed/refractory AITL. See also Clinical Trials Fact Sheet